3-nitrotyrosine and Capillary-Leak-Syndrome

Recombinant interleukin-2 (IL-2) therapy for malignancy is associated with a pulmonary vascular leakage syndrome (VLS) similar to that seen in sepsis. We investigated the possibility that the IL-2-induced VLS may be associated with the release of peroxynitrite (ONOO(-)), and used a model of IL-2-induced VLS in sheep to test the effects of the ONOO(-) decomposition catalyst WW-85. Eighteen sheep were chronically instrumented and randomly divided into three groups (n=6 per group): sham: lactated Ringer's solution, control: IL-2, and treatment: IL-2 and WW-85. Treatment with WW-85 significantly improved lung transvascular fluid flux, decreased lipid peroxidation, limited iNOS as well as PAR intensity, prevented tachycardia, and attenuated the increase in core body temperature resulting from IL-2 treatment. These findings suggest that ONOO(-) plays a pivotal role in the pathology of IL-2-induced pulmonary VLS, and that WW-85 may become a useful treatment option.

Topics: Animals; Capillary Leak Syndrome; Capillary Permeability; Catalysis; Hemodynamics; Interleukin-2; Lung; Lymph; Malondialdehyde; Neoplasms; Nitric Oxide; Nitric Oxide Synthase Type II; Peroxidase; Peroxynitrous Acid; Pulmonary Gas Exchange; Recombinant Proteins; Sheep; Tyrosine